Furthermore, we showed that CC1007 could significantly prolong median survival time of primary BCR-ABL1− pre-B-ALL-bearing mice, suggesting that CC1007 may represent an alternative molecular targeting strategy for BCR-ABL1− pre-B-ALL treatment. Here, BCR is linked to acute lymphoblastic leukemia.